AACR logo

More articles from Non-Checkpoint Immunotherapies

Abstract IA25: Synergistic innate and adaptive integrin-targeted immunotherapy
Karl Dane Wittrup

Cancer Immunology Research Nov 2016, 4 (11 Supplement) IA25; DOI: 10.1158/2326-6066.IMM2016-IA25
Abstract IA23: Microenvironmental regulation of antitumor immune responses: A lesson from fibroblastic cells
Viviana Cremasco, Angelo Grauel, Michael Wu, Jillian Astarita, Matthew Woodruff, Zohreh Amoozgar, Lotte Spel, Flavian Brown, Michael Carroll, Kenzie MacIsaac, Glenn Dranoff, Shannon Turley

Cancer Immunology Research Nov 2016, 4 (11 Supplement) IA23; DOI: 10.1158/2326-6066.IMM2016-IA23
Abstract IA24: New frontiers in oncolytic virus therapy
David M. Reese

Cancer Immunology Research Nov 2016, 4 (11 Supplement) IA24; DOI: 10.1158/2326-6066.IMM2016-IA24
Abstract PR10: Small-molecule inhibitors of CD73 promote activation of human CD8+ T cells and have profound effects on tumor growth and immune parameters in experimental tumors
Juan C. Jaen, Jay P. Powers, Ada Chen, Manmohan R. Leleti, Jarek Kalisiak, Ulrike Schindler, Joanne Bl Tan, Steve Young, Shin-Heng Chiou, Laurent Debien

Cancer Immunology Research Nov 2016, 4 (11 Supplement) PR10; DOI: 10.1158/2326-6066.IMM2016-PR10
Abstract PR11: Neo-antigen landscape dynamics during human melanoma-T cell interactions
Els M.E. Verdegaal, Noel de Miranda, Marten Visser, Tom Harryvan, Marit van Buuren, Rikke Andersen, Sine Hadrup, Caroline van der Minne, Remko Schotte, Hergen Spits, John Haanen, Ellen Kapiteijn, Ton Schumacher, Sjoerd H. Van Der Burg

Cancer Immunology Research Nov 2016, 4 (11 Supplement) PR11; DOI: 10.1158/2326-6066.IMM2016-PR11
Abstract B055: Augmentation of OX40-dependent NK mediated antitumor activity is dependent on antibody cross-linking
Sean H. Lim, Anna H. Turaj, Jane Willoughby, Claude H.T. Chan, Christine A. Penfold, Peter W.M. Johnson, Martin J. Glennie, Mark S. Cragg, Ronald Levy

Cancer Immunology Research Nov 2016, 4 (11 Supplement) B055; DOI: 10.1158/2326-6066.IMM2016-B055
Abstract B048: A novel PI3K delta inhibitor suppresses tumor progression by immune modulation
ZuSheng Xu, Yangtong Lou, Jie Tan, Chong Wang, Xiaomei Ge, Ying Gu, He Zhou

Cancer Immunology Research Nov 2016, 4 (11 Supplement) B048; DOI: 10.1158/2326-6066.IMM2016-B048
Abstract B050: Functional characterization of virus specific stem cell like memory T cells, their maturation in vitro, and potential contribution to secondary T cell responses
Tzu-yun Kuo, Aisha N. Hasan, Richard J. O'Reilly

Cancer Immunology Research Nov 2016, 4 (11 Supplement) B050; DOI: 10.1158/2326-6066.IMM2016-B050
Abstract B052: Peroxisome proliferator-activated receptor delta agonist GW501516 enhances the efficacy of adoptive cell therapy
Samuel Saibil, Michael St. Paul, Pamela Ohahsi

Cancer Immunology Research Nov 2016, 4 (11 Supplement) B052; DOI: 10.1158/2326-6066.IMM2016-B052
Abstract IA21: Immune mobilizing TCR therapies against cancer (ImmTAC): A novel class of antigen-specific tumor immunotherapy
Christina M. Coughlin

Cancer Immunology Research Nov 2016, 4 (11 Supplement) IA21; DOI: 10.1158/2326-6066.IMM2016-IA21

Main menu

User menu

Search

More articles from Non-Checkpoint Immunotherapies

Pages

Articles

Info for

About Cancer Immunology Research